Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Pharmaceutical giant Merck and its partner Ridgeback Biotherapeutics announced Monday that it has asked the Food and Drug Administration for emergency approval of its COVID-19 pill after the experimental drug showed “compelling results” in clinical trials.

Merck asks FDA for emergency approval of its antiviral COVID-19 pill

Molnupiravir, an oral antiviral, is shown in a late-stage trial to reduce the risk of hospitalization or death by around 50%.

Merck Submits Its Covid-19 Pill for Emergency FDA Approval. The Stock Is Down.

A late-stage trial showed the pill, which Merck is developing with Miami-based Ridgeback Therapeutics, halves the chances of hospitalization or death in recently diagnosed patients at risk of severe illness.

Merck Seeks U.S. Emergency Approval For Antiviral Covid Pill

Merck & Co. Inc. MRK, -1.60% and Ridgeback Biotherapeutics said Monday that Merck has submitted an application for Emergency Use Authorization (EUA) with the Food and Drug Administration for molnupiravir, their oral antiviral medicine for the treatment of mild-to-moderate COVID-19 in adults. The companies said the application followed positive results from a Phase 3 trial which showed that with adults at risk for progressing to severe COVID-19, molnupiravir reduced the risk of hospitalization or death by 50%.

Merck files for emergency authorization of COVID-19-treating pill

The Covid-19 treatment – known as molnupiravir – could be available to Americans by late this year.

Merck asks FDA to authorize antiviral Covid pill for emergency use

KENILWORTH, N.J. & MIAMI--(BUSINESS WIRE)---- $MRK #MRK--Merck and Ridgeback Announce Submission of Emergency Use Authorization Application to the U.S. FDA for Molnupiravir

Merck and Ridgeback Announce Submission of Emergency Use Authorization Application to the U.S. FDA for Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of Mild-to-Moderate COVID-19 in At Risk Adults

The drugmaker'd recent stock struggles present a terrific buying opportunity.

3 Reasons to Buy Merck Stock Right Now

Pfizer

The companies will vie for leadership in this billion-dollar market.

Better Bet on COVID Pills: Merck or Pfizer?

BENGALURU (Reuters) -Two Indian drugmakers have requested permission to end late-stage trials of their generic versions of Merck & Co's promising experimental oral antiviral drug molnupiravir to treat moderate COVID-19, a week after Merck said its own trial had succeeded for mild-to-moderate patients.

Two Indian drugmakers to end trials of generic Merck pill for moderate COVID-19

According to a source with the Drug Controller General of India, Merck & Co Inc's (NYSE: MRK) antiviral drug molnupiravir has not shown "significant efficacy" against moderate COVID-19. Related Link:   Merck's COVID-19 Oral Antiviral Cuts Risk of Hospitalization, Death By 50%.

Indian Study Shows Merck's COVID-19 Antiviral Candidate Less Effective Against Moderate Infection: Reuters

Costco

Freeport-McMoRan

Johnson & Johnson

Procter & Gamble

Here's why long-term investors seeking defensive stocks to buy right now may want to consider these top seven options right now. The post 7 Defensive Stocks to Buy and Forget About In Times of Volatility appeared first on InvestorPlace.

7 Defensive Stocks to Buy and Forget About In Times of Volatility

This partnership is showing early efficacy in the race for an oral COVID-19 treatment, but Atea and Roche are on their haunches.

Can This Duo Outperform Merck and Ridgeback Biotherapeutics' COVID Treatment?

Acceleron Pharma

Merck will pick up a promising pipeline candidate with the deal.

Is an Acquisition of Acceleron a Smart Move for Merck?

Biogen

Mirati Therapeutics

Even after recently agreeing to shell out $11.5 billion to acquire Acceleron Pharma Inc. ( XLRN , Financial), Merck & Co. Inc. ( MRK , Financial) says it's not done in its quest for deals aimed at diversifying its business. The more than $200 billion pharmaceutical giant wants to expand its offerings to soften the blow when its mega-blockbuster drug, Keytruda, loses patent protection around 2028, according to FiercePharma.

Biogen, Mirati and Arcturus Reportedly on Merck's Radar

Amgen

Bristol-Myers

British American Tobacco

Lockheed Martin

LyondellBasell Industries

Medical Properties Trust

Omega Healthcare Investors

Vedanta Limited

Vodafone Group

Viatris

ZIM Integrated Shipping Services

12 raises came from 49 dividend payers taking income sky high to its highest level ever. All are listed with dividend amount, yield, and other pertinent information. Portfolio value was down only 3.54%, better than most of the indexes and with income up dividend yield was 4.37%.

Rose 94 Stock Portfolio Q3/September Sky-High Dividends Update

Merck is looking for a miracle. Well, another one.

Merck Staring Down Patent Cliff of Its Lucrative Cancer Wonder Drug

Merck & Co Inc (NYSE: MRK) remains in a deal-hunting mode despite its recent $11.5 billion acquisition of Acceleron.  Related:   Merck Seals Acceleron Pharma Deal For $180/Share: Highlights.

Merck Keeps M&A Mode On With Mirati, Biogen, mRNA Companies On Radar: FT

Merck & Co., Inc. (NYSE:MRK) announced last week the oral COVID-19 pill it is co-developing with Ridgeback Biotherapeutics reduces the risk of hospitalization or death by 50%. The announcement triggered an across-the-board, steep sell-off in COVID-19 vaccine stocks.

Merck's Oral COVID-19 Treatment Could Be Game-Changer: BofA Analyst

Merck shares have jumped since the drug maker said molnupiravir cuts the risk of COVID hospitalization or death by about 50%.

Retail investors are dumping shares of COVID-19 vaccine makers and piling into antiviral pill maker Merck, data shows

Reuters reported that Merck & Co Inc (NYSE: MRK) has announced a supply and purchase agreement to provide Singapore with access to its experimental oral COVID-19 antiviral drug. Molnupiravir is designed to introduce errors into the virus's genetic code and be the first oral antiviral medication for COVID-19.

Merck Inks Supply Pact With Singapore For Its Oral COVID-19 Antiviral: Reuters

Molnupiravir results are striking for very early treatment, but this doesn't compare with vaccination; the time window for effect is short and the trial was mostly with unvaccinated people. Merck has a Phase 3 trial testing if molnupiravir can prevent infection of a person exposed to someone infected with COVID-19.

Merck Stock Up On Molnupiravir, But Don't Get Too Excited

Merck is ready to apply for authorization ahead of Pfizer.

Merck May Beat Pfizer to the COVID Pill Market. Does It Matter?

Could Pfizer's COVID Pill Be Better Than Merck's?

Home Depot

Altria

Invesco S&P 500 Equal Weight ETF

Schwab US Dividend Equity ETF

AT&T

Texas Instruments

Vanguard Total Stock Market ETF

SCHD has performed very well as investors have become less enthusiastic about the growth stocks that dominate VTI. We take an in-depth look at some of the valuation metrics and quant ratings of the top 25 stocks that make up 75% of SCHD's total value.

SCHD, RSP, Or VTI: Where To Deploy New Cash In A Correcting Market?

Boeing

Caterpillar

Cisco Systems

Chevron

Disney

Dow Inc

Intel

Coca-Cola

NIKE

Visa

Verizon

Walgreens

Walmart

"The Dow® [adds a stock] if the company has an excellent reputation, demonstrates sustained growth, and is of interest to a large number of investors. Sector representation.is also a consideration."

News for Merck Stock (MRK)